

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: **Jon A. Wolff,)**
Sean D. Monahan, James E. Hagstrom,)
Paul M. Slattum, Vladimir G. Budker,)
and David B. Rozema)
Serial No.: **09/312,351)**
Filed: **5/14/99)**
Group Art Unit: **1632)**

Examiner: **Joseph Woitach**



For: **A Compound Containing a Labile Disulfide Bond**

STATEMENT OF CONTENT FOR SEQUENCE LISTING
UNDER 37 C.F.R. §1.821

Commissioner of Patents
PO BOX 1450
Alexandria, VA 22313-1450

Dear Sir:

Sequence Listing:


An amendment to the specification was filed on March 13, 2003 (and with a corrected version of the amendment on Nov. 6, 2003) to include a sequence listing for the sequence found in the specification. A sequence listing paper copy was submitted along with a computer readable form (CRF). The sequence listing and that contained on the CRF are the same.

Respectfully submitted,



Kirk Ekena, Reg. No. 56,672
Mirus Bio Corporation
505 South Rosa Road
Madison, WI 53719
608.238.4400

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: 5/27/05.



Kirk Ekena